Investor · 1 deal
Every published round Otago Innovation Ltd took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Otago Innovation Ltd has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Amaroq Therapeutics | 8 Jul 2021 | 1 | 0 |
Fund closes reported for Otago Innovation Ltd, as distinct from the investments it has made.
Companies Otago Innovation Ltd has backed that another company then bought. An exit for the holding, not a deal Otago Innovation Ltd did.
Stories naming Otago Innovation Ltd. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.
New Zealand biotech Amaroq Therapeutics reported early progress toward clinical trials and appointed four leading scientists to its scientific advisory board, strengthening its lncRNA cancer therapy programme.
Brandon Capital's site announces it led $14m for Amaroq Therapeutics, an Otago spinout developing RNA-based cancer treatments — the firm's first deal as a government-backed incubator. The piece also recalls Kea Therapeutics' shutdown.
Brandon Capital led a NZ$14 million investment in Amaroq Therapeutics, a University of Otago spinout developing RNA cancer therapies, with three co-investors and a Callaghan Innovation repayable grant supporting the deal.
University of Otago cancer RNA spinout Amaroq Therapeutics has raised NZ$14 million led by Brandon Capital with Otago Innovation, NZ Innovation Booster and Cure Kids Ventures to advance its lncRNA-targeting cancer therapies.
Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio